Slide 1: NeoStem Overview
Exhibit 99.1 NeoStem® Overview Robin Smith, MD, MBA CEO and Chairman of the Board (NYSE AMEX: NBS) May 7, 2009
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements i this presentation constitute Yomarcooking statements” within the meaning of the Private Secures Liigation Reform Act of 1995. ‘These stotements include statements relating to NeoStem, Ine. (the “Campany/) in general as well as wit respect fo the Compan
Slide 3: NeoStem
NeoStem = Listed on the NYSE AMEX (ticker: NBS) = Have completed approximately $27 Million in financing through April 2009 = Leading operator of commercial autologous adult stem cell bank Pioneering pre-disease collection, processing and long-term storage of stem cells from adult donors. for their o
Slide 4: Adult Stem Cell Collection
Adult Stem Cell Collection Collecting Your Stem Cells is To Your Advantage = NeoStem has created a safe = Finding a “matching” donor is very difficult and minimally invasive way = People are dying while on the wait-list aor saa Tey eaten = High rejection rate due to “graft vs. host” cells collected
Slide 5: 70+ Diseases Treated w/Stem Cells
70+ Diseases Treated w/Stem Cells Results for many have been quite encouraging Heart Disease “It saved my life... my own stem cells.” BERNIE ‘Adult Stem Cell Heart Recipient Lupus "My Lupus has been in remission for #2 more than 5 years.” KatHy Adult Stem Cell Recipient Multiple Sclerosis “Stem Cell
Slide 6: Virtually All Therapeutic Areas
Virtually All Therapeutic Areas Over 2,300 Adult Stem Cell Clinical Trials * It is forecasted by the end of 2009, the first autologous products will be on the market in both orthopaedic and cardiovascular markets.* = By 2017, it is forecasted that a minimum of 16 stem cells products will be approved
Slide 7: Revenue Model
Revenue Model = Current: Collection center fees Collection fees from patients Processing and Storage fees (recurring revenue) Usage Fees Federal Funding (awarded) = Potential: o Increase revenue from international collection, processing & storage and usage fees Supplier of stem cells for research ©
Slide 8: NeoStem's Future Plan
— NeoStem’s Future Plan = Established and profitable traditional pharma business in China underpins stem cell platform rollout = Innovative and vertically-integrated regenerative medicine product offering and delivery platform provides high growth opportunity + Technological, R&D and management reso
Slide 9: Proposed Combined Company
— Proposed Combined Company revenues and earnings provide certain stability a that should be able to underpin the stem cell roliout Suan Pelee errs ‘Pharmaceutical products. NBS brings innovative stem cell technology as well as credibility and domain knowledge which Treatment will be a platform for
Slide 10: Suzhou Erye Pharmaceutical
— Suzhou Erye Pharmaceutical NBS signed agreement to acquire 51% ownership in Suzhou Erye Pharmaceutical Company in November 2008** © Provides asionger balance sheet and Ps phate revenues Ebi an pie atonal puma bushes ee Suu Jana aid earns © Estabished and pofabe taditonal pharma business located in
Slide 11: Stem Cell Businesses
— Stem Cell Businesses = Storage © Collection, processing and cryogenic preservation and storage of adult stem cells from peripheral biood for potential future regenerative medical treatment © There are no commercial scale providers that offer this service in China © Storage is one of the core busin
Slide 12: Nutritional Supplement
— Nutritional Supplement NeoStem signed an agreement with Ceres Living, Inc. a direct marketing company that developed AlO Premium Cellular Health, a liquid nutritional supplement. AlO was developed in conjunction with a leading nutritional laboratory and NeoStem’s scientists and Advisory Board memb
Slide 13: Intellectual Property
Intellectual Property = Patent Applications Pending on Platform Business: ° Collection of adult stem cells from peripheral blood of healthy individuals for future use to treat various diseases of the individual* ° Process by which NeoStem prepares and stores stem cells collected from peripheral bloo
Slide 14: Intellectual Property
Intellectual Property = Patent Applications Pending on Therapeutic Uses of Stem Cells: o Vincent Falanga 0 Composition and Methods Using Stem Cells in Cutaneous Wound Healing o Vincent Giampapa o Method and Composition for Restoration of Age-Related Tissue Loss in the Face or Selected Areas of the B
Slide 15: Very-Small Embryonic-like Stem Cells (VSELs)
Very-Small Embryonic-like Stem Cells (VSELs) i 1D unpuntied C8 WNC WE CXGR4* CD34" ACT39* Lin COS 10005 Leukemia (2006), 1-7 . * Morphological and molecular characterization of novel population of CXCR4* SSEA-4* Gera very sell embryonicdike ells porled from buram cord tlood = pretiraary | a> & 100}
Slide 16: Current Capitalization
Current Capitalization Preferred stock; authorized, 5,000,000 shares Series B convertible preferred stock, authorized, 825,000 shares Series D convertible preferred stock, authorized, 880,000 shares* ‘Common stock, authorized, 500,000,000 shares; ‘Warrants Outstanding Stock Options Outstanding Avera
Slide 17: Comparables
— Comparables Sue SB ots ct untae taal wast sa ever mascap a Some sam | ‘mice "gh Ww nascin vite _tevnve C804 eons _"Aa Vr Cf /tev BA” BOB PH /8 ety seman cates) sitet | moe 200 23M AG} 3) Seaham ets tees au | oom 0am ae ska} Sakae Soca fea | oss ism sim © 9B) Game Ree Wocarowetmectyray ac «| 72500
Slide 18: Current Advisory Board Members
Current Advisory Board Members Wayne A. Marasco, M.D. Ph. Chairman -Chaisman of Scieniic Advisory Board. Associate Professor-Department of Cancer and immunology & AIDS atthe Dana-Farber Cancér Insitute and Associate Professor of Medicine t Harvard Medical Schoo. He Te taking the lead In expanding th
Slide 19: Contact Information
Contact Information Robin Smith, MD MBA NeoStem, Inc. Chairman & CEO 420 Lexington Avenue Direct: (212) 584-4174 Suite 450 Email: rsmith@neostem.com New York, NY 10170 Main: (212) 584-4180 Fax: (646) 514-7787 www.neostem.com 1.888.STEM BANK